NCT06468579

To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Completed Phase 1 Last updated 23 October 2024

What this trial tests

Phase 1 trial testing GT20029 in Acne in 92 participants. Completed in 26 April 2023.

Timeline

25 July 2021

Primary endpoint
15 August 2022

26 April 2023

Quick facts

Lead sponsor	Suzhou Kintor Pharmaceutical Inc,
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	92
Start date	25 July 2021
Primary completion	15 August 2022
Estimated completion	26 April 2023
Sites	1 location across China

Drugs / interventions tested

• GT20029
• GT20029 matching placebo — full drug profile →

Conditions studied

• Acne — all drugs for Acne →
• Alopecia — all drugs for Alopecia →

Sponsor

Suzhou Kintor Pharmaceutical Inc, — full company profile →

Who can join

Adults 18 to 60, any sex, with Acne or Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a randomized, double-blind, vehicle-controlled, parallel group, phase 1 study to evaluate the Safety, Tolerability and PK of GT20029 in healthy subjects

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
   Fan G, Chen S, Zhang Q, Yu N, et al · · 2025 · cited 6× · PMID 41049269 · DOI 10.1002/mco2.70401
2. Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery.
   Gioiello L, Di Martino RMC, Pirali T. · · 2025 · cited 2× · PMID 41255358 · DOI 10.1021/acs.jmedchem.5c01911
3. PROTAC-based protein degradation: a window of opportunity for melanoma therapy.
   Gentile G, D'Aguanno S, Di Martile M, Petricca A, et al · · 2026 · PMID 41761284 · DOI 10.1186/s12929-026-01225-2